Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Fibroscan use to help diagnose acute heart failure in the emergency department

Official title: Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department

Run by Assistance Publique - Hôpitaux de Paris · NCT07449377 · Data updated 2026-11-12

This study tests whether a FibroScan device can quickly help doctors identify acute heart failure in adults who come to the ED with sudden shortness of breath.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations1 site (Paris)
StatusRecruiting
StartedApril 2, 2026
Main results expectedMay 2027
Study endsMay 2027
Registry record updatedOctober 27, 2026
Trial IDNCT07449377 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older presenting to the ED with acute dyspnea and no other obvious cause of dyspnea are ideal candidates.

Probably not a fit

Patients with chronic liver disease, very low kidney function, pregnancy, or those outside the ED setting may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this intervention study, researchers assess the use of FibroScan to measure liver stiffness as a potential marker of venous congestion in patients with suspected acute heart failure presenting to the emergency department. The goal is to see if liver stiffness measurements can provide rapid bedside information to aid diagnosis when traditional tests may be delayed or limited. Eligible adults with acute dyspnea and no clear alternative cause can undergo FibroScan as part of their ED assessment. The trial is sponsored by AP-HP with collaboration from Echosens and is conducted at the Paris Pitié-Salpêtrière ED.

Why it matters

Potential benefit: If successful, FibroScan could offer a faster, non-invasive clue to diagnose acute heart failure at the bedside.

How similar studies have gone: Previous research suggests a correlation between liver stiffness and venous congestion in heart failure, supporting a potential role for this approach in acute settings, though evidence in ED-acute presentations is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients ≥18 years
2. ED patients presenting with acute dyspnea and absence of any other obvious cause of dyspnea (for example pneumothorax, acute pneumonia, acute coronary syndrome, Covid) …
3. Social security affiliation (except AME)
4. Informed consent signed

Exclusion Criteria:

1. Known chronic liver disease, defined by a Prothrombic time of \< 50%, or any former diagnosis of liver fibrosis.
2. No skin wounds in the abdominal area on which the Fibroscan® will be used
3. History of liver transplantation
4. eGFR \<30 mL/min
5. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom
6. Pregnancy and breastfeeding
7. Participation in another interventional trial

Where it's running

  • Name: Emergency Department Hospital Pitié-Salpêtrière, APHP
    Paris, France
    Recruiting

Study contacts

  • Principal investigator: Amélie VROMANT, Medical Doctor — Assistance Publique - Hôpitaux de Paris
  • Study coordinator: Amélie VROMANT, Medical Doctor
  • Email: amelie.vromant@aphp.fr
  • Phone: +33617253512

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.